<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509131</url>
  </required_header>
  <id_info>
    <org_study_id>PMF105BC1/09</org_study_id>
    <nct_id>NCT01509131</nct_id>
  </id_info>
  <brief_title>Evaluation of a Mixed Bowel Prep (2L PEG + Bisacodyl) Versus PEG With Ascorbate</brief_title>
  <official_title>Low Volume Bowel Preparation for Colonoscopy: a Comparison Between PEG-CS Plus Bisacodyl Versus PEG-ASC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promefarm S.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promefarm S.r.l.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that PEG 2L with citrate and simeticone plus bisacodyl will have similar
      bowel cleansing efficacy versus PEG 2L with ascorbate. Safety, tolerability, acceptance and
      compliance of the two reduced volume PEG-based bowel preparation will be also compared.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the quality of bowel preparation by BBPS</measure>
    <time_frame>20 minutes</time_frame>
    <description>BBPS is an established rating scale to evaluate the quality of bowel preparation. A score greater than 6 is considered as success. The rate of success will be compared between the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in mucosal visibility between the two groups</measure>
    <time_frame>20 minutes</time_frame>
    <description>Three point rating scale(0-2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>Patient questioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in tolerability between the two groups</measure>
    <time_frame>24 hours</time_frame>
    <description>Difference in the percentage of patients in the two groups who developed GI symptoms related to bowel preparation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in patients acceptability between the two groups</measure>
    <time_frame>24 hours</time_frame>
    <description>Difference in the percentage of patients in the two groups who were willing to repeat the preparation and easy to take the bowel preparation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in patients compliance between the two groups</measure>
    <time_frame>24 hours</time_frame>
    <description>Difference in the percentage of patients who took at least 75% of bowel preparation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>2L PEG-CS plus bisacodyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be asked to take 2L PEG-CS plus bisacodyl (10-20 mg according to patient bowel habit)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2L PEG-ASC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be asked to take PEG-ASC according to labeling instructions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2L PEG-CS plus bisacodyl</intervention_name>
    <description>Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)</description>
    <arm_group_label>2L PEG-CS plus bisacodyl</arm_group_label>
    <other_name>Lovolesse 2L plus Lovoldyl 5 mg (2-4 tablets)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2L PEG-ASC</intervention_name>
    <description>Patients will asked to take PEG-ASC according to labeling instructions</description>
    <arm_group_label>2L PEG-ASC</arm_group_label>
    <other_name>Moviprep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Out-patients undergoing a complete colonoscopy

          -  Patient written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating women or at a risk of becoming pregnant

          -  Hypersensitivity to any of the ingredients

          -  History of anaphylaxis to drugs or allergic reactions in general

          -  Known or suspected gastrointestinal obstruction or perforation

          -  Toxic megacolon; major colonic resection

          -  Heart failure (Class III or IV); severe renal failure; relevant diseases, that may
             interfere with the aim of the study

          -  Phenylketonuria;Glucose-6-phosphate dehydrogenase deficiency

          -  Unwillingness to co-operate and to comply with the requirements of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Repici, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCSS Istituto Clinico Humanitas, Rozzano (MI) - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renzo Cestari, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spedali Civili di Brescia, Brescia - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cesare Hassan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuovo Regina Margherita, Roma - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angelo Andriulli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo - Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vito Annese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Careggi, Firenze - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Regina Margherita</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>January 11, 2012</last_update_submitted>
  <last_update_submitted_qc>January 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisacodyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

